{"disease":{"id":"erbb2-mutation-related-tumors","name":"erbb2 mutation related tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06185400","title":"RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":108,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07122882","title":"Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}